AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis
(RTTNews) - AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ 15 mg, once daily) for the treatment of adult patients with giant cell arteritis (GCA).
GCA is an autoimmune disease of medium and large arteries and can cause headache, jaw pain, and changes in vision, including sudden and permanent loss of vision. The regulatory submissions to the FDA and EMA are supported by previously announced results from the SELECT-GCA Phase 3 study evaluating the safety and efficacy of upadacitinib in patients with GCA.
read more
AbbVie Boosts FY24 Outlook - Update
While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2024.
RTTNews
|
123 dni temu
AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients
AbbVie, Inc. (ABBV) announced Tuesday that a new weight-based oral solution RINVOQ LQ (upadacitinib) is now available as an option for pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
RTTNews
|
174 dni temu
AbbVie To Acquire Landos Biopharma At $20.42/share In Cash
AbbVie Inc. (ABBV) and Landos Biopharma, Inc. (LABP) announced Monday a definitive agreement under which AbbVie will acquire biopharmaceutical company Landos.
RTTNews
|
245 dni temu
AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO
AbbVie, Inc. (ABBV) announced Tuesday that its board of directors has unanimously selected Robert Michael, AbbVie's current president and chief operating officer, to succeed Richard Gonzalez as the company's chief executive officer.
RTTNews
|
279 dni temu
AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln
AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
RTTNews
|
361 dni temu
AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin
Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The trial demonstrated compelling clinical benefits across key endpoints.
RTTNews
|
362 dni temu
AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint
AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.
RTTNews
|
423 dni temu
AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab
Biopharmaceutical company AbbVie, Inc. (ABBV) announced Tuesday top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg subcutaneous injection [SC] starting at week 12 and every 8 weeks thereafter) versus ustekinumab (STELARA, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) through week 48 in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.
RTTNews
|
440 dni temu
